JP2012508265A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508265A5 JP2012508265A5 JP2011535792A JP2011535792A JP2012508265A5 JP 2012508265 A5 JP2012508265 A5 JP 2012508265A5 JP 2011535792 A JP2011535792 A JP 2011535792A JP 2011535792 A JP2011535792 A JP 2011535792A JP 2012508265 A5 JP2012508265 A5 JP 2012508265A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 49
- 150000003839 salts Chemical class 0.000 claims 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 7
- 125000000732 arylene group Chemical group 0.000 claims 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 6
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 6
- 229910052760 oxygen Inorganic materials 0.000 claims 6
- 239000001301 oxygen Substances 0.000 claims 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 239000011593 sulfur Substances 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000005549 heteroarylene group Chemical group 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010061218 Inflammation Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical group 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 208000017520 skin disease Diseases 0.000 claims 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 201000002832 Lewy body dementia Diseases 0.000 claims 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 238000010276 construction Methods 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 241001303601 Rosacea Species 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 206010040880 Skin irritation Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 235000010290 biphenyl Nutrition 0.000 claims 1
- 239000004305 biphenyl Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 229960002842 clobetasol Drugs 0.000 claims 1
- CBGUOGMQLZIXBE-XGQKBEPLSA-N clobetasol propionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CCl)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CBGUOGMQLZIXBE-XGQKBEPLSA-N 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 1
- 150000002430 hydrocarbons Chemical group 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000008929 regeneration Effects 0.000 claims 1
- 238000011069 regeneration method Methods 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 230000036556 skin irritation Effects 0.000 claims 1
- 231100000475 skin irritation Toxicity 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 210000003523 substantia nigra Anatomy 0.000 claims 1
- MWQHQPJKOHDVMP-UHFFFAOYSA-N CC(C([IH]I)=O)N(C(c1c2cccc1)=O)C2=O Chemical compound CC(C([IH]I)=O)N(C(c1c2cccc1)=O)C2=O MWQHQPJKOHDVMP-UHFFFAOYSA-N 0.000 description 1
- 0 CC(Cc(cc1)ccc1O)NC(C*C(Cc(cc1)ccc1O)NC(C)=O)=O Chemical compound CC(Cc(cc1)ccc1O)NC(C*C(Cc(cc1)ccc1O)NC(C)=O)=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11349808P | 2008-11-11 | 2008-11-11 | |
| US61/113,498 | 2008-11-11 | ||
| PCT/US2009/064077 WO2010056778A1 (en) | 2008-11-11 | 2009-11-11 | Isoprenyl compounds and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014153690A Division JP6132818B2 (ja) | 2008-11-11 | 2014-07-29 | イソプレニル化合物およびその方法。 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508265A JP2012508265A (ja) | 2012-04-05 |
| JP2012508265A5 true JP2012508265A5 (enExample) | 2012-12-27 |
| JP5611967B2 JP5611967B2 (ja) | 2014-10-22 |
Family
ID=42170308
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011535792A Expired - Fee Related JP5611967B2 (ja) | 2008-11-11 | 2009-11-11 | イソプレニル化合物およびその方法。 |
| JP2014153690A Expired - Fee Related JP6132818B2 (ja) | 2008-11-11 | 2014-07-29 | イソプレニル化合物およびその方法。 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014153690A Expired - Fee Related JP6132818B2 (ja) | 2008-11-11 | 2014-07-29 | イソプレニル化合物およびその方法。 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US8372884B2 (enExample) |
| EP (3) | EP3330252B1 (enExample) |
| JP (2) | JP5611967B2 (enExample) |
| CN (1) | CN102209701B (enExample) |
| AU (3) | AU2009314165B2 (enExample) |
| CA (1) | CA2780624A1 (enExample) |
| DK (1) | DK2362866T3 (enExample) |
| ES (1) | ES2549158T3 (enExample) |
| HK (1) | HK1256397A1 (enExample) |
| PT (1) | PT2362866E (enExample) |
| WO (1) | WO2010056778A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| PT2362866E (pt) | 2008-11-11 | 2015-10-26 | Signum Biosciences Inc | Compostos de isoprenila e métodos dos mesmos |
| US8461204B2 (en) | 2008-11-11 | 2013-06-11 | Signum Biosciences, Inc. | Cysteinyl compounds, compositions and methods of use |
| PL2498603T3 (pl) * | 2009-11-12 | 2017-03-31 | Signum Biosciences, Inc. | Zastosowanie środków przeciwbakteryjnych do leczenia chorób związanych z nabłonkiem |
| US8483375B2 (en) * | 2010-03-19 | 2013-07-09 | Avaya, Inc. | System and method for joining conference calls |
| RU2696487C2 (ru) | 2013-03-06 | 2019-08-02 | Аллерган, Инк. | Применение агонистов формилпептидного рецептора 2 для лечения дерматологических заболеваний |
| ES2831092T3 (es) | 2014-12-23 | 2021-06-07 | Crossing S R L | Método para la producción industrial de 2-halo-4,6-dialcoxi-1,3,5-triazinas y su uso en presencia de aminas |
| WO2016124239A1 (en) | 2015-02-04 | 2016-08-11 | Aurealis Oy | Recombinant probiotic bacteria for use in the treatment of a skin dysfunction |
| US20160296443A1 (en) * | 2015-04-08 | 2016-10-13 | Cgtn C.V. | Skin care composition having skin damage prevention and damage repairing properties |
| KR20180081501A (ko) | 2015-09-24 | 2018-07-16 | 드렉셀유니버시티 | 진피 장애를 치료하거나 예방하는 신규한 조성물 및 방법 |
| JP6880011B2 (ja) * | 2015-10-05 | 2021-06-02 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 皮膚美白組成物 |
| TW201726123A (zh) * | 2015-10-17 | 2017-08-01 | 辛格納生物科學公司 | 用於增加基因表現之調配物 |
| WO2018031427A1 (en) * | 2016-08-08 | 2018-02-15 | Dermata Therapeutics, Llc | Pharmaceutical formulations and their use |
| WO2018031571A1 (en) * | 2016-08-08 | 2018-02-15 | Signum Biosciences, Inc. | Pharmaceutical formulations and their use |
| JP7073384B2 (ja) * | 2017-01-13 | 2022-05-23 | シグナム バイオサイエンシーズ， インコーポレイテッド | 化合物及び使用方法 |
| US12116443B2 (en) * | 2020-06-16 | 2024-10-15 | Johnson & Johnson Vision Care, Inc. | Amino acid-based polymerizable compounds and ophthalmic devices prepared therefrom |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4622417A (en) | 1984-12-27 | 1986-11-11 | General Foods Corporation | L-aminodicarboxylic-(O-cycloalkyl)-L-aminocarboxylate alkyl ester sweeteners |
| US4638071A (en) * | 1984-12-27 | 1987-01-20 | General Foods Corporation | Cycloalkyl ethers and thioethers of dipeptides |
| US4603011A (en) * | 1985-05-24 | 1986-07-29 | General Foods Corporation | L-aminodicarboxylic acid amides of alkoxyalkylamines |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| US5043268A (en) * | 1990-05-04 | 1991-08-27 | The Trustees Of Princeton University | Substrates and inhibitors for prenyl cysteine methyltransferase enzymes |
| US5202456A (en) * | 1991-04-15 | 1993-04-13 | The President And Fellows Of Harvard College | Compounds for inhibition of protein methylation |
| US5965539A (en) | 1993-05-18 | 1999-10-12 | Univeristy Of Pittsburgh | Inhibitors of prenyl transferases |
| US5482710A (en) | 1993-07-30 | 1996-01-09 | Chesebrough-Pond'usa Co., Division Of Conopco, Inc. | Cosmetic composition for treatment of pimples and redness |
| US5571687A (en) * | 1994-06-07 | 1996-11-05 | Duke University | Modulators of multidrug resistance transporters |
| US5491164A (en) | 1994-09-29 | 1996-02-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6015877A (en) * | 1996-03-14 | 2000-01-18 | President And Fellows Of Harvard College | Compounds for inhibition of proteolysis |
| AU739469B2 (en) | 1996-12-20 | 2001-10-11 | Alza Corporation | Gel composition and methods |
| US6193991B1 (en) | 1997-10-29 | 2001-02-27 | Atul J. Shukla | Biodegradable delivery systems of biologically active substances |
| US6251882B1 (en) | 1998-06-29 | 2001-06-26 | Parker Hughes Institute | Alkyl ketones as potent anti-cancer agents |
| JP2002519341A (ja) * | 1998-06-29 | 2002-07-02 | パーカー ヒューズ インスティテュート | 強力な抗がん剤としてのアルキルケトン類 |
| DE10146737A1 (de) * | 2001-09-22 | 2003-04-10 | Aventis Pharma Gmbh | Coniosulfide und deren Derivate, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel |
| US6927236B2 (en) | 2001-09-22 | 2005-08-09 | Aventis Pharma Deutschland Gmbh. | Coniosulfides and their derivatives, processes for preparing them, and their use as pharmaceuticals |
| CA2522147A1 (en) | 2003-03-26 | 2004-10-14 | Purdue Research Foundation | Compounds and methods for use in treating neoplasia and cancer based upon inhibitors of isoprenylcysteine methyltransferase |
| US8338648B2 (en) * | 2004-06-12 | 2012-12-25 | Signum Biosciences, Inc. | Topical compositions and methods for epithelial-related conditions |
| US7745589B1 (en) * | 2005-07-21 | 2010-06-29 | University Of Kentucky Research Foundation | Antibodies and unnatural substrates of prenylation enzymes for use in detecting and isolating prenylated proteins |
| EP2240019A4 (en) * | 2007-12-03 | 2011-11-16 | Signum Biosciences Inc | MIMETIC ACID COMPOUNDS FOR INHIBITING ISOPRENYL-S-CYSTEINYL METHYLTRANSFERASE |
| WO2009094534A1 (en) | 2008-01-24 | 2009-07-30 | Signum Biosciences, Inc. | Improved method for preparing isoprenyl cysteine compounds and analogs thereof |
| AU2009214493A1 (en) * | 2008-02-14 | 2009-08-20 | Signum Biosciences, Inc. | Acetyl mimic compounds for the inhibition of isoprenyl-S-cysteinyl methyltransferase |
| PT2362866E (pt) | 2008-11-11 | 2015-10-26 | Signum Biosciences Inc | Compostos de isoprenila e métodos dos mesmos |
| US8461204B2 (en) * | 2008-11-11 | 2013-06-11 | Signum Biosciences, Inc. | Cysteinyl compounds, compositions and methods of use |
| WO2010090845A1 (en) | 2009-01-20 | 2010-08-12 | Signum Biosciences, Inc. | Anti-inflammatory complexes |
-
2009
- 2009-11-11 PT PT98266919T patent/PT2362866E/pt unknown
- 2009-11-11 CN CN200980144838.5A patent/CN102209701B/zh not_active Expired - Fee Related
- 2009-11-11 ES ES09826691.9T patent/ES2549158T3/es active Active
- 2009-11-11 EP EP18150768.2A patent/EP3330252B1/en active Active
- 2009-11-11 EP EP09826691.9A patent/EP2362866B1/en active Active
- 2009-11-11 WO PCT/US2009/064077 patent/WO2010056778A1/en not_active Ceased
- 2009-11-11 JP JP2011535792A patent/JP5611967B2/ja not_active Expired - Fee Related
- 2009-11-11 DK DK09826691.9T patent/DK2362866T3/en active
- 2009-11-11 EP EP15175731.7A patent/EP2963012B1/en not_active Not-in-force
- 2009-11-11 AU AU2009314165A patent/AU2009314165B2/en not_active Ceased
- 2009-11-11 CA CA2780624A patent/CA2780624A1/en not_active Abandoned
- 2009-11-12 US US12/616,781 patent/US8372884B2/en active Active - Reinstated
-
2013
- 2013-02-06 US US13/760,627 patent/US9376383B2/en active Active
-
2014
- 2014-07-29 JP JP2014153690A patent/JP6132818B2/ja not_active Expired - Fee Related
- 2014-08-11 AU AU2014210669A patent/AU2014210669B2/en not_active Ceased
-
2016
- 2016-05-10 US US15/151,221 patent/US9744147B2/en not_active Expired - Fee Related
- 2016-09-16 AU AU2016228304A patent/AU2016228304B2/en not_active Ceased
-
2017
- 2017-08-01 US US15/665,922 patent/US10314802B2/en active Active
-
2018
- 2018-12-04 HK HK18115503.8A patent/HK1256397A1/en unknown